RANITOPHTAL Trademark

Trademark Overview

On Friday, October 5, 2018, a trademark application was filed for RANITOPHTAL with the United States Patent and Trademark Office. The USPTO has given the RANITOPHTAL trademark a serial number of 79244286. The federal status of this trademark filing is REGISTERED as of Tuesday, October 8, 2019. This trademark is owned by Klinge Pharma GmbH. The RANITOPHTAL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of angiogenesis and ocular diseases and disorders
ranitophtal

General Information

Serial Number79244286
Word MarkRANITOPHTAL
Filing DateFriday, October 5, 2018
Status700 - REGISTERED
Status DateTuesday, October 8, 2019
Registration Number5876432
Registration DateTuesday, October 8, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 23, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of angiogenesis and ocular diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 7, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameKlinge Biopharma GmbH
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDE
Party NameKlinge Biopharma GmbH
Party Type21 - New Owner After Publication
Legal Entity Type99 - Other
AddressDE
Party NameKlinge Pharma GmbH
Party Type20 - Owner at Publication
Legal Entity Type27 - NOT AVAILABLE
AddressHolzkirchen 83607
DE
Party NameKlinge Pharma GmbH
Party Type10 - Original Applicant
Legal Entity Type27 - NOT AVAILABLE
AddressHolzkirchen 83607
DE

Trademark Events

Event DateEvent Description
Wednesday, January 16, 2019ASSIGNED TO EXAMINER
Thursday, November 1, 2018SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, November 7, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, November 13, 2018APPLICATION FILING RECEIPT MAILED
Wednesday, January 23, 2019NON-FINAL ACTION WRITTEN
Thursday, January 24, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, February 5, 2019REFUSAL PROCESSED BY MPU
Tuesday, February 5, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, February 22, 2019REFUSAL PROCESSED BY IB
Wednesday, June 12, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, June 12, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, June 14, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 14, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 14, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 17, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 3, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, July 17, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, July 23, 2019PUBLISHED FOR OPPOSITION
Tuesday, July 23, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, August 2, 2019NOTIFICATION PROCESSED BY IB
Thursday, August 15, 2019CHANGE OF OWNER RECEIVED FROM IB
Tuesday, October 8, 2019REGISTERED-PRINCIPAL REGISTER
Thursday, October 10, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 10, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, December 10, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 17, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, January 8, 2020REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
Wednesday, January 8, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, February 1, 2020FINAL DISPOSITION PROCESSED
Friday, June 4, 2021NEW REPRESENTATIVE AT IB RECEIVED
Friday, April 1, 2022NEW REPRESENTATIVE AT IB RECEIVED
Sunday, May 26, 2024NEW REPRESENTATIVE AT IB RECEIVED
Friday, February 21, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Saturday, February 1, 2020FINAL DISPOSITION NOTICE SENT TO IB

Related Keywords

ranitophtal diseases disorders ocular angiogenesis preparations treatment pharmaceutical